Aditxt Inc.'s Subsidiary Pearsanta Invited to Submit Full Proposal for U.S. Department of Defense’s OCRP Pilot Award

Aditxt Inc. (NASDAQ: ADTX) has reached a pivotal moment as its subsidiary, Pearsanta, Inc., receives an invitation to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award. This invitation comes after a positive evaluation of Pearsanta’s pre-proposal, which underscored the scientific merit and innovative approach of its Mitomic(R) Ovarian Test (MOT(TM)). The MOT(TM) is a groundbreaking blood-based diagnostic tool aimed at the early detection of ovarian cancer, a disease notorious for its late-stage diagnosis and poor survival rates.

The potential grant, offering up to $350,000 over two years, is earmarked for the validation of the MOT(TM) through a multi-center clinical study. This validation is a critical step toward the test's commercial launch as a laboratory-developed test. The development of the MOT(TM) represents a beacon of hope for improving early detection rates and, consequently, patient outcomes in the battle against ovarian cancer.

Aditxt Inc. stands at the forefront of health technology innovation, functioning as a social innovation platform. The company collaborates with a network of research institutions, industry partners, and shareholders to fast-track the development and implementation of cutting-edge health solutions. Aditxt’s current portfolio includes programs focused on immune health and precision health, with ambitions to extend into public health and women’s health sectors through strategic partnerships with Appili Therapeutics Inc. and Evofem. For further details on Aditxt Inc. and its pioneering projects, visit https://www.Aditxt.com.